Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Medicinal Chemistry
  4. Volume 32, Issue 2
  5. Article
Volume 32, Issue 2
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Morbidity, disability, and healthcare expenses associated with rheumatoid arthritis (RA) impose a considerable health and economical burden on both patients and healthcare systems. This review aimed to examine the pathophysiological aspects of RA that may help design different types of drugs and drug delivery systems. These include monoclonal antibodies, immunoglobulins, tiny chemicals, and transgenes for gene therapy. These novel nanocarrier-based therapies target the underlying biological processes involved in RA while minimizing the systemic adverse effects of drugs.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867331666230815112818
2024-09-06
2025-04-15

  • From This Site

    /content/journals/cmc/10.2174/0929867331666230815112818
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. GuoQ. WangY. XuD. NossentJ. PavlosN.J. XuJ. Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies.Bone Res.2018611510.1038/s41413‑018‑0016‑929736302
     [Google Scholar]
  2. Ben MridR. BouchmaaN. AinaniH. El FatimyR. MalkaG. MaziniL. Anti-rheumatoid drugs advancements: New insights into the molecular treatment of rheumatoid arthritis.Biomed. Pharmacother.202215111312610.1016/j.biopha.2022.11312635643074
     [Google Scholar]
  3. BatkoB. KorkoszM. JuśA. WilandP. Management of rheumatoid arthritis in Poland where daily practice might not always meet evidence-based guidelines.Arch. Med. Sci.20211751286129310.5114/aoms.2019.8409234522257
     [Google Scholar]
  4. Mu oz-Mart nezC. Segura-PuertasM. G mez-MorenoG. Disease-modifying Antirheumatic Drugs (DMARDs) and drug interactions in dentistry.Eur. Rev. Med. Pharmacol. Sci.20212572834284233877648
     [Google Scholar]
  5. TanakaY. Recent progress in treatments of rheumatoid arthritis: An overview of developments in biologics and small molecules, and remaining unmet needs.Rheumatology (Oxford)202160Suppl. 6vi12vi2010.1093/rheumatology/keab60934951925
     [Google Scholar]
  6. ShuklaA. MaitiP. Nanomedicine and versatile therapies for cancer treatment.Med. Comm.202233e16310.1002/mco2.163
     [Google Scholar]
  7. SargentJ. New nanomedicines for treating atherosclerotic plaques.Nat. Rev. Endocrinol.201511525610.1038/nrendo.2015.3525752278
     [Google Scholar]
  8. MoosavianS.A. SathyapalanT. JamialahmadiT. SahebkarA. The emerging role of nanomedicine in the management of nonalcoholic fatty liver disease: A state-of-the-art review.Bioinorg. Chem. Appl.20211011310.1155/2021/4041415
     [Google Scholar]
  9. OroojalianF. KarimzadehS. JavanbakhtS. HejaziM. BaradaranB. WebsterT.J. MokhtarzadehA. VarmaR.S. KesharwaniP. SahebkarA. Current trends in stimuli-responsive nanotheranostics based on metal organic frameworks for cancer therapy.Mater. Today20225719222410.1016/j.mattod.2022.05.024
     [Google Scholar]
  10. SanatiM. AfshariA.R. KesharwaniP. SukhorukovV.N. SahebkarA. Recent trends in the application of nanoparticles in cancer therapy: The involvement of oxidative stress.J. Control. Release202234828730410.1016/j.jconrel.2022.05.03535644289
     [Google Scholar]
  11. BarendregtA. Markers of inflammation: Measuring disease activity in juvenile idiopathic arthritis using imaging and immunological biomarkers.Graduate School Amsterdam Gastroenterology Endocrinology Metabolism (AMC)2019
     [Google Scholar]
  12. ElshalM. Abu-ElsaadN. El-KarefA. Retinoic acid modulates IL-4, IL-10 and MCP-1 pathways in immune mediated hepatitis and interrupts CD4+ T cells infiltration.Int. Immunopharmacol.201975105808
     [Google Scholar]
  13. BurmesterG.R. PopeJ.E. Novel treatment strategies in rheumatoid arthritis.Lancet2017389100862338234810.1016/S0140‑6736(17)31491‑5
     [Google Scholar]
  14. YapH.Y. TeeS. WongM. ChowS.K. PehS.C. TeowS.Y. Pathogenic role of immune cells in rheumatoid arthritis: implications in clinical treatment and biomarker development.Cells201871016110.3390/cells710016130304822
     [Google Scholar]
  15. RaduA.F. BungauS.G. Management of rheumatoid arthritis: An overview.Cells20211011285710.3390/cells1011285734831081
     [Google Scholar]
  16. McInnesI.B. SchettG. The pathogenesis of rheumatoid arthritis.N. Engl. J. Med.2011365232205221910.1056/NEJMra100496522150039
     [Google Scholar]
  17. AletahaD. SmolenJ.S. Diagnosis and management of rheumatoid arthritis.JAMA2018320131360137210.1001/jama.2018.1310330285183
     [Google Scholar]
  18. HuangJ. FuX. ChenX. LiZ. HuangY. LiangC. Promising therapeutic targets for treatment of rheumatoid arthritis.Front. Immunol.20211268615510.3389/fimmu.2021.68615534305919
     [Google Scholar]
  19. GiacomelliR. AfeltraA. AlunnoA. BaldiniC. Bartoloni-BocciE. BerardicurtiO. International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management.Autoimmun Rev.2017169911924
     [Google Scholar]
  20. MohammedR.H.A. Introductory chapter: Rheumatoid arthritis - overview of current facts and strategies.Rheumatoid ArthritisIntechopen LimitedLondon2020
     [Google Scholar]
  21. NagyG. RoodenrijsN.M. WelsingP.M. KedvesM. HamarA. Van Der GoesM.C. EULAR definition of difficult-to-treat rheumatoid arthritis.Ann. Rheum. Dis.2021809313510.1136/annrheumdis‑2020‑217344
     [Google Scholar]
  22. WassonJ.H. SoxH.C. NeffR.K. GoldmanL. Clinical prediction rules. Applications and methodological standards.N. Engl. J. Med.19853131379379910.1056/NEJM1985092631313063897864
     [Google Scholar]
  23. WakefieldR.J. GreenM.J. Marzo-OrtegaH. ConaghanP.G. GibbonW.W. McGonagleD. ProudmanS. EmeryP. Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease.Ann. Rheum. Dis.200463438238510.1136/ard.2003.00706215020331
     [Google Scholar]
  24. PilaniaR.K. SinghS. Rheumatology panel in pediatric practice.Indian Pediatr.201956540741410.1007/s13312‑019‑1538‑y31102381
     [Google Scholar]
  25. IngegnoliF. CastelliR. GualtierottiR. Rheumatoid factors: Clinical applications.Dis. Markers201335672773410.1155/2013/72659824324289
     [Google Scholar]
  26. GirelliF. FoschiF.G. BedeschiE. CalderoniV. StefaniniG.F. MartinelliM.G. Is anti cyclic citrullinated peptide a useful laboratory test for the diagnosis of rheumatoid arthritis?Eur. Ann. Allergy Clin. Immunol.200436412713015180353
     [Google Scholar]
  27. Alende-CastroV. Alonso-SampedroM. Vazquez-TempranoN. Tu ezC. ReyD. Garc a-IglesiasC. Sope aB. GudeF. Gonzalez-QuintelaA. Factors influencing erythrocyte sedimentation rate in adults.Medicine (Baltimore)20199834e1681610.1097/MD.000000000001681631441853
     [Google Scholar]
  28. CrowsonC.S. RahmanM.U. MattesonE.L. Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis.J. Rheumatol.20093681606161010.3899/jrheum.08118819531760
     [Google Scholar]
  29. ArnettF.C. EdworthyS.M. BlochD.A. McshaneD.J. FriesJ.F. CooperN.S. HealeyL.A. KaplanS.R. LiangM.H. LuthraH.S. MedsgerT.A. MitchellD.M. NeustadtD.H. PinalsR.S. SchallerJ.G. SharpJ.T. WilderR.L. HunderG.G. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis.Arthritis Rheum.198831331532410.1002/art.17803103023358796
     [Google Scholar]
  30. ZamanR. XiangY. CruzJ. Frequency and anatomic distribution of magnetic resonance imaging features in the sacroiliac joints of young athletes: Exploring background noise toward a data-driven definition of sacroiliitis in early spondyloarthritis.Arthritis Rheumatol.2018705736745
     [Google Scholar]
  31. HungI.F.-N. LungK.C. TsoE.Y.K. LiuR. ChungT.W.H. ChuM.Y. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: An open-label, randomised, phase 2 trial.Lancet2020395102381695170410.1016/S0140‑6736(20)31042‑4
     [Google Scholar]
  32. WeberU. JurikA.G. ZejdenA. LarsenE. RgensenS.H. RufibachK. Frequency and anatomic distribution of magnetic resonance imaging lesions in the sacroiliac joints of spondyloarthritis and non-spondyloarthritis patients.Sage J.201870573645
     [Google Scholar]
  33. Pawlik-SobeckaL. G rka-DynysiewiczJ. Kuciel-LewandowskaJ.J.A.S. Balneotherapy with the use of radon sulphide water.Mech. Ther. Eff.20211162849
     [Google Scholar]
  34. RegueiroC. Rodr guez-Mart nezL. Nu oL. OrtizA.M. VillalbaA. Pascual-SalcedoD. Improved RA classification among early arthritis patients with the concordant presence of three RA autoantibodies: Analysis in two early arthritis clinics.Arthritis Res Ther.20192128010.1186/s13075‑019‑2079‑4
     [Google Scholar]
  35. EnglandB.R. TiongB.K. BergmanM.J. CurtisJ.R. KaziS. MikulsT.R. 2019 Update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures.Arthritis Care Res. (Hoboken)20197112154055
     [Google Scholar]
  36. LewisM.J. BarnesM.R. BligheK. GoldmannK. RanaS. HackneyJ.A. Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes.Cell Rep.20192892455247010.1016/j.celrep.2019.07.091
     [Google Scholar]
  37. BehrensF. BurmesterG.R. FeuchtenbergerM. KellnerH. KuehneC. LiebhaberA. Characterisation of depressive symptoms in rheumatoid arthritis patients treated with tocilizumab during routine daily care.Clin. Exp. Rheumatol.2022403551559
     [Google Scholar]
  38. BrownJ.R. Frontiers in rheumatoid arthritis: Introduction.Am. J. Health-Sys. Pharm.20066318S2
     [Google Scholar]
  39. KeanW.F. KeanI.R.L. Clinical pharmacology of gold.Inflammopharmacology200816311212510.1007/s10787‑007‑0021‑x18523733
     [Google Scholar]
  40. KavinayaA. An Open comparative clinical evaluation on Uthiravadha Suronitham (Rheumatoid Arthritis) with siddha herbal mineral formulation drug Samuthara Chooranam (Internal), Vadha Noiku Veliprayogha Thailam (External) & Ottradam.ChennaiGovernment Siddha Medical College2018
     [Google Scholar]
  41. Chatman-TerryV. Leptin level variance in adults with and without cancer. Doctoral Dissertation, Walden University.2019
     [Google Scholar]
  42. SternakM. BarA. AdamskiM.G. MohaissenT. MarczykB. KieronskaA. The deletion of endothelial sodium channel α (αENaC) impairs endothelium-dependent vasodilation and endothelial barrier integrity in endotoxemia in vivo.Front Pharmacol.20189178
     [Google Scholar]
  43. SandhuR.S. TreharneG.J. DouglasK.M.J. CassimK. SaratzisA. PiperH. ErbN. JenkinsD. TavakoliM. DeightonC. KitasG.D. The impact of anti-tumour necrosis factor therapy for rheumatoid arthritis on the use of other drugs and hospital resources in a pragmatic setting.Musculoskelet. Care20064420422210.1002/msc.9217117445
     [Google Scholar]
  44. SinghJ.A. SaagK.G. BridgesS.L.Jr AklE.A. BannuruR.R. SullivanM.C. VaysbrotE. McNaughtonC. OsaniM. ShmerlingR.H. CurtisJ.R. FurstD.E. ParksD. KavanaughA. O DellJ. KingC. LeongA. MattesonE.L. SchousboeJ.T. DrevlowB. GinsbergS. GroberJ. St ClairE.W. TindallE. MillerA.S. McAlindonT. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis.Arthritis Care Res. (Hoboken)201668112510.1002/acr.2278326545825
     [Google Scholar]
  45. De BandtM. Anti-TNF-alpha-induced lupus.Arthritis Res. Ther.201921123510.1186/s13075‑019‑2028‑231718696
     [Google Scholar]
  46. KimK.U. KimJ. KimW.H. MinH. Treatments of inflammatory bowel disease toward personalized medicine.Arch. Pharm. Res.2021443293309
     [Google Scholar]
  47. HamannP. HollandR. HyrichK. PaulingJ.D. ShaddickG. NightingaleA. McHughN. Factors associated with sustained remission in rheumatoid arthritis in patients treated with anti-tumor necrosis factor.Arthritis Care Res. (Hoboken)201769678379310.1002/acr.2301627564526
     [Google Scholar]
  48. BuchM.H. EyreS. McGonagleD.J.N.R.R. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis.Nat Rev Rheumatol.20211711733
     [Google Scholar]
  49. GaeddertA. Healing digestive disorders: Natural treatments for gastrointestinal conditions.PMPH USA, Ltd.United States2018
     [Google Scholar]
  50. Rubbert-RothA. Szab M.Z. KedvesM. NagyG. AtzeniF. Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents.Autoimmun. Rev.20191812102398
     [Google Scholar]
  51. CapellH.A. MadhokR. PorterD.R. MunroR.A.L. McInnesI.B. HunterJ.A. StevenM. ZomaA. MorrisonE. SambrookM. Wui PoonF. HampsonR. McDonaldF. TierneyA. HendersonN. FordI. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: Results from the double-blind placebo-controlled MASCOT study.Ann. Rheum. Dis.200666223524110.1136/ard.2006.05713316926184
     [Google Scholar]
  52. SmolenJ.S. PanganA.L. EmeryP. RigbyW. TanakaY. VargasJ.I. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (select-monotherapy): A randomised, placebo-controlled, double-blind phase 3 study.Lancet.20193931018823032311
     [Google Scholar]
  53. KragsnaesM.S. SødergrenS.T. KjeldsenJ. HornH.C. MunkH.L. PedersenJ.K. Experiences and perceptions of patients with psoriatic arthritis participating in a trial of faecal microbiota transplantation: A nested qualitative study.BMJ Open.2021113e03947110.1136/bmjopen‑2020‑039471
     [Google Scholar]
  54. DavidV. WalshM. LockyerJ. MintzM. OleynickC. MotazedianP. The SARS-CoV-19 pandemic one year later.Gen. Int. Med.202116161
     [Google Scholar]
  55. van RielP.L.C.M. TaggartA.J. SanyJ. GaubitzM. NabH.W. PedersenR. FreundlichB. MacPeekD. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: The ADORE study.Ann. Rheum. Dis.200665111478148310.1136/ard.2005.04329916464988
     [Google Scholar]
  56. OrbellS. Automatic processes and self-regulation of illness.Health. Psychol. Rev.2019134378405
     [Google Scholar]
  57. Van HeckeO. RaymondM. LeeJ.J. TurnerP. GoyderC.R. VerbakelJ.Y. In-vitro diagnostic point-of-care tests in paediatric ambulatory care: A systematic review and meta-analysis.PlusOne2020157e023560510.1371/journal.pone.0235605
     [Google Scholar]
  58. Oon, S.; Huq, M.; Godfrey, T.; Nikpour, M. Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus. Semin. Arthritis Rheumatism, 2018, 48(2), 221-239. WB Saunders.10.1016/j.semarthrit.2018.01.001
  59. LeiguardaC. PotilinskiC. RubioneJ. TateP. VillarM.J. MontanerA. IMT504 provides analgesia by modulating cell infiltrate and inflammatory milieu in a chronic pain model.J. Neuroimmune. Pharmacol.2021163651666
     [Google Scholar]
  60. YuZ. ReynaudF. LorscheiderM. TsapisN. FattalE.J.W.I.R.N. Nanomedicines for the delivery of glucocorticoids and nucleic acids as potential alternatives in the treatment of rheumatoid arthritis.Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.20201245e1630
     [Google Scholar]
  61. ParagliolaR.M. PapiG. PontecorviA. Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis.Int. J. Mol. Sci.201718102201
     [Google Scholar]
  62. VadellA.K. BärebringL. HulanderE. GjertssonI. LindqvistH.M. Anti-inflammatory diet in rheumatoid arthritis (ADIRA) a randomized, controlled crossover trial indicating effects on disease activity.Am. J. Clin. Nutr.2020111612031213
     [Google Scholar]
  63. FerraF. CeccatoF. CannavS. What we have to know about corticosteroids use during SARS-CoV-2 infection.J. Endocrinol. Invest.2021444693701
     [Google Scholar]
  64. GreenD. DalmayT. The role of small RNAs in Paget's associated osteosarcoma.J. Bone Oncol.20181354
     [Google Scholar]
  65. SimpsonE. HockE. StevensonM. WongR. DracupN. WailooA. What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis.Health. Technol. Assess.201822201258
     [Google Scholar]
  66. RaoM. IppolitoG. MfinangaS. NtoumiF. Yeboah- ManuD. VilaplanaC. Improving treatment outcomes for MDR-TB novel host-directed therapies and personalised medicine of the future.Int. J. Infect. Dis.201980S20S62S67
     [Google Scholar]
  67. RichesS. KhanF. KwiederS. Impact of an auditory hallucinations simulation on trainee and newly qualified clinical psychologists: A mixed-methods cross-sectional study.Clin. Psychol. Psychother.2019263277290
     [Google Scholar]
  68. HochbergM. COX-2 selective inhibitors in the treatment of arthritis: A rheumatologist perspective.Curr. Top. Med. Chem.20055544344810.2174/156802605420169515974939
     [Google Scholar]
  69. YangX. LiM. JiangJ. HuX. QingY. SunL. Dysregulation of phospholipase and cyclooxygenase expression is involved in Schizophrenia.EBioMedicine20216410323910.1016/j.ebiom.2021.103239
     [Google Scholar]
  70. HalpernG.M. Ulcer Free!: Nature s Safe Effective Remedy for Ulcers.New YorkSquare One Publishers, Inc.2004
     [Google Scholar]
  71. BullockJ. RizviS.A.A. SalehA.M. AhmedS.S. DoD.P. AnsariR.A. AhmedJ. Rheumatoid arthritis: A brief overview of the treatment.Med. Princ. Pract.201827650150710.1159/00049339030173215
     [Google Scholar]
  72. PhamC.T.N. Nanotherapeutic approaches for the treatment of rheumatoid arthritis.Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.20113660761910.1002/wnan.15721837725
     [Google Scholar]
  73. HuG. GuoM. XuJ. WuF. FanJ. HuangQ. YangG. LvZ. WangX. JinY. Nanoparticles targeting macrophages as potential clinical therapeutic agents against cancer and inflammation.Front. Immunol.201910199810.3389/fimmu.2019.0199831497026
     [Google Scholar]
  74. DeightonC. CriswellL.A. Recent advances in the genetics of rheumatoid arthritis.Curr. Rheumatol. Rep.20068539440010.1007/s11926‑006‑0071‑x16973114
     [Google Scholar]
  75. OzbakirB. CrielaardB.J. MetselaarJ.M. StormG. LammersT. Liposomal corticosteroids for the treatment of inflammatory disorders and cancer.J. Control. Release201419062463610.1016/j.jconrel.2014.05.03924878183
     [Google Scholar]
  76. AltenR. D ringG. CutoloM. Gromnica-IhleE. WitteS. StraubR. ButtgereitF. Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone.J. Rheumatol.201037102025203110.3899/jrheum.10005120682671
     [Google Scholar]
  77. BartneckM. PetersF.M. WarzechaK.T. BienertM. van BlooisL. TrautweinC. LammersT. TackeF. Liposomal encapsulation of dexamethasone modulates cytotoxicity, inflammatory cytokine response, and migratory properties of primary human macrophages.Nanomedicine20141061209122010.1016/j.nano.2014.02.01124607939
     [Google Scholar]
  78. Gomez-BarrenaE. LindroosL. CeponisA. L pez-FrancoM. Sanchez-PernauteO. M nkk nenJ. SaloJ. Herrero-BeaumontG. KonttinenY. Cartilage oligomeric matrix protein (COMP) is modified by intra-articular liposomal clodronate in an experimental model of arthritis.Clin. Exp. Rheumatol.200624662262817207376
     [Google Scholar]
  79. CeponisA. WarisE. M nkk nenJ. LaasonenL. HyttinenM. SolovievaS.A. HanemaaijerR. BitschA. KonttinenY.T. Effects of low-dose, noncytotoxic, intraarticular liposomal clodronate on development of erosions and proteoglycan loss in established antigen-induced arthritis in rabbits.Arthritis Rheum.20014481908191610.1002/1529‑0131(200108)44:8<1908::AID‑ART329>3.0.CO;2‑411508444
     [Google Scholar]
  80. LiS. SuJ. CaiW. LiuJ. Nanomaterials manipulate macrophages for rheumatoid arthritis treatment.Front. Pharmacol.20211269924510.3389/fphar.2021.69924534335264
     [Google Scholar]
  81. JorgensenC. ApparaillyF. Prospects for gene therapy in inflammatory arthritis.Best Pract. Res. Clin. Rheumatol.201024454155210.1016/j.berh.2010.02.00120732651
     [Google Scholar]
  82. GhoshS. BrownA.M. JenkinsC. CampbellK. Viral vector systems for gene therapy: A comprehensive literature review of progress and biosafety challenges.Appl. Biosaf.202025171810.1177/153567601989950236033383
     [Google Scholar]
  83. DuanW. LiH. Combination of NF-kB targeted siRNA and methotrexate in a hybrid nanocarrier towards the effective treatment in rheumatoid arthritis.J. Nanobiotechnology20181615810.1186/s12951‑018‑0382‑x30060740
     [Google Scholar]
  84. KhouryM. Louis-PlenceP. EscriouV. NoelD. LargeauC. CantosC. SchermanD. JorgensenC. ApparaillyF. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor α in experimental arthritis.Arthritis Rheum.20065461867187710.1002/art.2187616729293
     [Google Scholar]
  85. KhouryM. EscriouV. CourtiesG. GalyA. YaoR. LargeauC. SchermanD. JorgensenC. ApparaillyF. Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes.Arthritis Rheum.20085882356236710.1002/art.2366018668557
     [Google Scholar]
  86. NagataY. NakasaT. MochizukiY. IshikawaM. MiyakiS. ShibuyaH. YamasakiK. AdachiN. AsaharaH. OchiM. Induction of apoptosis in the synovium of mice with autoantibody-mediated arthritis by the intraarticular injection of double-stranded microRNA-15a.Arthritis Rheum.20096092677268310.1002/art.2476219714650
     [Google Scholar]
  87. SobusK.M. Rehabilitation care and management for the individual with cerebral palsy, ages 13 through early adulthood.Crit. Rev. Phys. Rehabil. Med.2009212117165
     [Google Scholar]
  88. ChenM. DaddyJ.C.K.A. XiaoY. PingQ. ZongL. Advanced nanomedicine for rheumatoid arthritis treatment: Focus on active targeting.Expert Opin. Drug Deliv.201714101141114410.1080/17425247.2017.137274628847165
     [Google Scholar]
  89. XiaoS. TangY. LvZ. LinY. ChenL. Nanomedicine advantages for their use in rheumatoid arthritis theranostics.J. Control. Release201931630231610.1016/j.jconrel.2019.11.00831715278
     [Google Scholar]
  90. Nakashima-MatsushitaN. HommaT. YuS. MatsudaT. SunaharaN. NakamuraT. TsukanoM. RatnamM. MatsuyamaT. Selective expression of folate receptor? and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis.Arthritis Rheum.19994281609161610.1002/1529‑0131(199908)42:8<1609::AID‑ANR7>3.0.CO;2‑L10446858
     [Google Scholar]
  91. SioutiE. AndreakosE. The many facets of macrophages in rheumatoid arthritis.Biochem. Pharmacol.201916515216910.1016/j.bcp.2019.03.02930910693
     [Google Scholar]
  92. CostaC. IncioJ. SoaresR. Angiogenesis and chronic inflammation: Cause or consequence?Angiogenesis200710314916610.1007/s10456‑007‑9074‑017457680
     [Google Scholar]
  93. SzekaneczZ. BesenyeiT. Szentp tery KochA.E. Angiogenesis and vasculogenesis in rheumatoid arthritis.Curr. Opin. Rheumatol.201022329930610.1097/BOR.0b013e328337c95a20305562
     [Google Scholar]
  94. MerchantB. Gold, the noble metal and the paradoxes of its toxicology.Biologicals1998261495910.1006/biol.1997.01239637749
     [Google Scholar]
  95. TsaiC.Y. ShiauA.L. ChenS.Y. ChenY.H. ChengP.C. ChangM.Y. ChenD.H. ChouC.H. WangC.R. WuC.L. Amelioration of collagen-induced arthritis in rats by nanogold.Arthritis Rheum.200756254455410.1002/art.2240117265489
     [Google Scholar]
  96. KimW.U. LeeW.K. RyooJ.W. KimS.H. KimJ. YounJ. MinS.Y. BaeE.Y. HwangS.Y. ParkS.H. ChoC.S. ParkJ.S. KimH.Y. Suppression of collagen-induced arthritis by single administration of poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen: A novel treatment strategy for induction of oral tolerance.Arthritis Rheum.20024641109112010.1002/art.1019811953991
     [Google Scholar]
  97. NagashimaM. WaukeK. HiranoD. IshigamiS. AonoH. TakaiM. SasanoM. YoshinoS. Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis.Rheumatology (Oxford)200039111255126210.1093/rheumatology/39.11.125511085806
     [Google Scholar]
  98. FernandesJ.C. WangH. JreyssatyC. BenderdourM. LavigneP. QiuX. WinnikF.M. ZhangX. DaiK. ShiQ. Bone-protective effects of nonviral gene therapy with folate-chitosan DNA nanoparticle containing interleukin-1 receptor antagonist gene in rats with adjuvant-induced arthritis.Mol. Ther.20081671243125110.1038/mt.2008.9918500247
     [Google Scholar]
  99. CourtiesG. BaronM. PresumeyJ. EscriouV. van LentP. SchermanD. CantagrelA. van den BergW.B. JorgensenC. ApparaillyF. DavignonJ.L. Cytosolic phospholipase A2α gene silencing in the myeloid lineage alters development of Th1 responses and reduces disease severity in collagen-induced arthritis.Arthritis Rheum.201163368169010.1002/art.3017421360497
     [Google Scholar]
  100. HowardK.A. PaludanS.R. BehlkeM.A. BesenbacherF. DeleuranB. KjemsJ. Chitosan/siRNA nanoparticle- mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model.Mol. Ther.200917116216810.1038/mt.2008.22018827803
     [Google Scholar]
  101. ButoescuN. SeemayerC.A. FotiM. JordanO. DoelkerE. Dexamethasone-containing PLGA superparamagnetic microparticles as carriers for the local treatment of arthritis.Biomaterials20093091772178010.1016/j.biomaterials.2008.12.01719135244
     [Google Scholar]
  102. HwangJ. RodgersK. OliverJ.C. SchluepT. Alpha-methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy.Int. J. Nanomedicine20083335937118990945
     [Google Scholar]
  103. MetselaarJ.M. WaubenM.H.M. Wagenaar-HilbersJ.P.A. BoermanO.C. StormG. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes.Arthritis Rheum.20034872059206610.1002/art.1114012847701
     [Google Scholar]
  104. AriasJ.L. L pez-ViotaM. L pez-ViotaJ. DelgadoV. Development of iron/ethylcellulose (core/shell) nanoparticles loaded with diclofenac sodium for arthritis treatment.Int. J. Pharm.20093821-227027610.1016/j.ijpharm.2009.08.01919712736
     [Google Scholar]
  105. LiuM. HuangY. HuL. LiuG. HuX. LiuD. YangX. Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion.BMC Biotechnol.20121216810.1186/1472‑6750‑12‑6823006786
     [Google Scholar]
  106. CoppietersK. DreierT. SilenceK. HaardH.D. LauwereysM. CasteelsP. BeirnaertE. JonckheereH. WieleC.V.D. StaelensL. HostensJ. RevetsH. RemautE. ElewautD. RottiersP. Formatted anti tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis.Arthritis Rheum.20065461856186610.1002/art.2182716736523
     [Google Scholar]
  107. ThaoL.Q. ByeonH.J. LeeC. LeeS. LeeE.S. ChoiH.G. ParkE.S. YounY.S. Pharmaceutical potential of tacrolimus-loaded albumin nanoparticles having targetability to rheumatoid arthritis tissues.Int. J. Pharm.20164971-226827610.1016/j.ijpharm.2015.12.00426657273
     [Google Scholar]
  108. FiehnC. NeumannE. WunderA. KrienkeS. GayS. M ller-LadnerU. Methotrexate (MTX) and albumin coupled with MTX (MTX-HSA) suppress synovial fibroblast invasion and cartilage degradation in vivo.Ann. Rheum. Dis.200463788488610.1136/ard.2003.01374815194591
     [Google Scholar]
  109. LeeH. LeeM.Y. BhangS.H. KimB.S. KimY.S. JuJ.H. KimK.S. HahnS.K. Hyaluronate-gold nanoparticle/tocilizumab complex for the treatment of rheumatoid arthritis.ACS Nano2014854790479810.1021/nn500685h24730974
     [Google Scholar]
  110. DuanJ. DongJ. ZhangT. SuZ. DingJ. ZhangY. MaoX. Polyethyleneimine-functionalized iron oxide nanoparticles for systemic siRNA delivery in experimental arthritis.Nanomedicine (Lond.)20149678980110.2217/nnm.13.21724392891
     [Google Scholar]
  111. SamarasingheR.M. KanwarR.K. KanwarJ.R. The effect of oral administration of iron saturated-bovine lactoferrin encapsulated chitosan-nanocarriers on osteoarthritis.Biomaterials201435267522753410.1016/j.biomaterials.2014.04.10924933511
     [Google Scholar]
  112. LeeS.J. LeeA. HwangS.R. ParkJ.S. JangJ. HuhM.S. JoD.G. YoonS.Y. ByunY. KimS.H. KwonI.C. YounI. KimK. TNF-α gene silencing using polymerized siRNA/thiolated glycol chitosan nanoparticles for rheumatoid arthritis.Mol. Ther.201422239740810.1038/mt.2013.24524145554
     [Google Scholar]
  113. KimM.J. ParkJ.S. LeeS.J. JangJ. ParkJ.S. BackS.H. BahnG. ParkJ.H. KangY.M. KimS.H. KwonI.C. JoD.G. KimK. Notch1 targeting siRNA delivery nanoparticles for rheumatoid arthritis therapy.J. Control. Release201521614014810.1016/j.jconrel.2015.08.02526282098
     [Google Scholar]
  114. ZhouH. HuG. WicklineS.A. LanzaG.M. PhamC.T.N. Synergistic effect of antiangiogenic nanotherapy combined with methotrexate in the treatment of experimental inflammatory arthritis.Nanomedicine (Lond.)2010571065107410.2217/nnm.10.7820874021
     [Google Scholar]
  115. HeoR. ParkJ.S. JangH.J. KimS.H. ShinJ.M. SuhY.D. JeongJ.H. JoD.G. ParkJ.H. Hyaluronan nanoparticles bearing γ-secretase inhibitor: In vivo therapeutic effects on rheumatoid arthritis.J. Control. Release201419229530010.1016/j.jconrel.2014.07.05725109660
     [Google Scholar]
  116. ScheinmanR.I. TrivediR. VermillionS. KompellaU.B. Functionalized STAT1 siRNA nanoparticles regress rheumatoid arthritis in a mouse model.Nanomedicine (Lond.)20116101669168210.2217/nnm.11.9022087799
     [Google Scholar]
  117. YeJ. WangQ. ZhouX. ZhangN. Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis.Int. J. Pharm.20083521-227327910.1016/j.ijpharm.2007.10.01418054182
     [Google Scholar]
  118. AroraR. KuhadA. KaurI.P. ChopraK. Curcumin loaded solid lipid nanoparticles ameliorate adjuvant-induced arthritis in rats.Eur. J. Pain201519794095210.1002/ejp.62025400173
     [Google Scholar]
  119. AggarwalB.B. HarikumarK.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases.Int. J. Biochem. Cell Biol.2009411405910.1016/j.biocel.2008.06.01018662800
     [Google Scholar]
  120. SrinathP. CharyM.G. VyasS.P. DiwanP.V. Long-circulating liposomes of indomethacin in arthritic rats - a biodisposition study.Pharm. Acta Helv.200074439940410.1016/S0031‑6865(00)00023‑610812940
     [Google Scholar]
/content/journals/cmc/10.2174/0929867331666230815112818
Loading
Recent Advances in Drug Delivery Approaches for Rheumatoid Arthritis
Curr. Med. Chem. 32, 396 (2025); https://doi.org/10.2174/0929867331666230815112818
/content/journals/cmc/10.2174/0929867331666230815112818
/content/journals/cmc/10.2174/0929867331666230815112818
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): combination drug therapy; drug delivery; nanocarriers; nanomedicine; nanotherapeutics; Rheumatoid arthritis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test